维普期刊资源整合服务平台（V6.5）

102篇 您的检索式：作者名="Pivot X"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer显示文摘	JOHNSTON S P1PPEN J J R PIVOT X		0，，33：	1
2	Clinical staging for male breast cancer:an adaptation of the international classification (TNM)显示文摘	Pivot X Llombart CA Rhor AA		0，，：	1
3	Ixabepilone, a novel epothilone analog in the treatment of breast cancer 显示文摘	Pivot X Villanueva C Chaigneau L	2008	Expert Opin Investig Drugs2008，17，4：	1
4	Randomized phase II study of sunitinib versus standard of care for patients with pre- viously treated advanced triple-negative breast cancer 显示文摘	Curigliano G Pivot X Cortrs J	2013	Breast2013，22，5：	1
5	Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue 显示文摘	Villanueva C Dufresne A Pivot X	2008	Bull Cancer2008，95，2：	1
6	Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer显示文摘	Johnston S Pippen J Jr Pivot X	2009	J Clin Oncol2009，27，33：	1
7	The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy显示文摘	Magen N Pivot X Bensadoun RJ	2001	EurJ Cancer2001，37，17：	1
8	CEREBEL (EGF111438): A Phase ]1I, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer显示文摘	Pivot X Manikhas A Zurawski B	2015	J Clin Oncol2015，33，14：	1
9	Efficacy and safety of ixa-- 5epilone(BMS- 247550)in a phase IIs tudy of patients with ad- zanced breast cancer resistant to an anthraeyeline, a tslxane, and apecitabine 显示文摘	PEREZ EA LERZO G PIVOT X et a/	2007	J Clin Oncology2007，25，23：	1
10	A retrospective study of first indicators of breast cancer recurrence显示文摘	Pivot X Asmar L Hortobaqyi GN	2000	Oncology2000，58，3：	1
11	Adjuvant chemotherapy for local relapse breast cancer显示文摘	PIVOT X	2014	Lancet Oncol2014，15，2：	1
12	Co-variables influencing 5-fluorouracil clearance during continuous venous infusion显示文摘	Etienne MC Chatelut E Pivot X	1998	Eur J Cancer1998，34，1：	1
13	Pharmacokinetics of low - dose carboplatin and applicability of a method of ealculation for estimating individual drug clearance显示文摘	MC Etienne F Leger X Pivot	2003	Ann Oncol2003，14，：	1
14	The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer:Clinical expe- rience with anti-angiogenic agents, focusing on bevacizunmb 显示文摘	Marty M Pivot X	2008	Eur J Cancer2008，44，7：	1
15	PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast Cancer显示文摘	Pivot X Romieu G Bonnefoi H	2012	Ann Oncol2012，，9：	1
16	Efficacy and safety of ixabepilone, a novel epothilone analogue 显示文摘	Pivot X Dufresne A Villanueva C	2007	Clin Breast Cancer2007，7，7：	1
17	Randomized phase II trial of first - line trastuzumab plus docetaxel and capecitabine com- pared with trastuzumab plus docetaxel in HER2 - positive metastatic breast cancer显示文摘	Wardley AM Pivot X Morales - Vasquez F	2010	J Clin Oneo12010，28，6：	1
18	Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases:a randomized open-label equivalence trial显示文摘	Pivot X Lortholary A Abadie-Lacourtoisie S		0，，06：	1
19	6 months veiBus 12 monthsof adjuvant trastuzumab for patients with HER2 -positive early breastcancer(PHARE) :a randomised phase 3 triaI显示文摘	Pivot X Romieu G Debled M	2013	Landet Oncology2013，14，8：	1
20	Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer显示文摘	Chan A Miles DW Pivot X	2010	Ann Oncol2010，21，12：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示